OCT 04, 2016 2:17 PM PDT

Surgical Robot Can Remove Throat Tumors Without a Single Cut

WRITTEN BY: Xuan Pham
Robotic surgery sounds like the stuff of science fiction, but reality is quickly catching up. In particular, a system called the TransOral Robotic Surgery (TORS) was able to help oropharyngeal cancer patients recover from tumor surgery without any incisions.
 


Head and neck squamous cell carcinoma (HNSCC) is the sixth common cancer worldwide. These include cancers of the tongue, tonsils, soft palate and pharynx. Each year there are nearly 650,000 new cases and 350,000 deaths.
 
Conventional surgery techniques for these cancers can often lead to significant pain and disfigurement. By contrast, TORS, part of the da Vinci Surgical system proved to be much less invasive. The robotic system purportedly allows surgeons to get to the tumor via the mouth – no open incision on the face necessary.
 
By eliminating open wounds for the patients, doctors at the Henry Ford hospital found that patients recovered much quicker, some within mere days after surgery. "Within our study, patients treated with robotic surgery had excellent results and survival, irrespective of their p16 status,” said Tamer Ghanem, director of Head and Neck Oncology and Reconstructive Surgery Division in the Department of Otolaryngology-Head & Neck Surgery at Henry Ford Hospital, and the study’s lead author.
 

P16 is a protein marker of the human papilloma virus (HPV). The presence of the HPV type 16 virus is linked to oropharyngeal cancer. This status also appears to influence how well or how poorly a patient responds to treatment
 
"For non-surgical patients, several studies have shown that p16 positive throat cancers, or HPV- related throat cancers, have better survival and less recurrence than p16 negative throat cancers," said Ghanem.
 
In their study, the team analyzed a total of 53 patients with oropharyngeal cancer patients. Of this, 81 percent had HPV16+ oropharyngeal cancer.
 
Despite the p16 status, the study showed that the TORS robotic surgery was directly correlated with high survival and low cancer recurrence. In addition, the outcome appears to also improve when TORS was used in conjunction with chemotherapy or radiation therapy. Furthermore, the success of the surgery enabled lower doses of radiation, which benefited patients by reducing unwanted side effects.
 
Additional sources: Henry Ford Health System, Mayo clinic
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
MAR 23, 2020
Cancer
MAR 23, 2020
An Alternative Use for Common Kidney Cancer Drug to Fight Against Epithelial Ovarian Cancer
Axitinib is a small molecule drug that inhibits VEGFR tyrosine kinases 1, 2, and 3. Shown previously to potentially prev ...
MAR 30, 2020
Cancer
MAR 30, 2020
Cervical cancer screening affected by natural disasters
It may not come as a surprise that public health is adversely affected by natural disasters and conflict. New research p ...
APR 13, 2020
Cancer
APR 13, 2020
The Unexpected Role of Mono in Cancer Progression
In the past, the go-to drugs have always been small molecules. These small molecules would interact with the cell and ac ...
MAY 17, 2020
Cancer
MAY 17, 2020
Text message reminders don't cut it
New research published in the Journal of Clinical Oncology shows that contrary to previous investigations’ results ...
MAY 13, 2020
Drug Discovery & Development
MAY 13, 2020
Approved Treatment for RET-mutant Cancers
A drug was recently approved for treating three types of RET-mutant cancers: 1) non-small cell lung cancer (NSCLC) 2) ad ...
MAY 29, 2020
Cancer
MAY 29, 2020
What can we do about drug-induced tetraploidy in cancer cells?
A paper published in the journal Trends in Cancer describes how cancer therapies sometimes fuel genetic changes in cells ...
Loading Comments...